| Family Hearing Centers | |
|
2001 Lincoln Dr W, Suite E, Marlton, NJ 08053-1531 | |
| (856) 596-9670 | |
| (856) 985-6302 |
| Full Name | Family Hearing Centers |
|---|---|
| Type | Facility |
| Speciality | Audiologist-hearing Aid Fitter |
| Location | 2001 Lincoln Dr W, Marlton, New Jersey |
| Accepts Medicare Assignments | Does not participate in Medicare Program. The facility may not accept medicare assignment. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1639109499 | NPI | - | NPPES |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 231H00000X | Audiologist | (* (Not Available)) | Primary |
| 237600000X | Audiologist-hearing Aid Fitter | (* (Not Available)) | Primary |
| Mailing Address | Practice Location Address |
|---|---|
| Family Hearing Centers 2001 Lincoln Dr W, Suite E, Marlton, NJ 08053-1531 Ph: (856) 596-9670 | Family Hearing Centers 2001 Lincoln Dr W, Suite E, Marlton, NJ 08053-1531 Ph: (856) 596-9670 |
News Archive
BDNews24.com reports on a new $13 million U.S.-government initiative aimed at "providing HIV-prevention services to two million at-risk people in Bangladesh including injecting drug users, male, female and transgender sex workers and their clients, and HIV-positive people through a network of 50 health centres." USAID will partner with Family Health International (FHI) to implement the program (9/17).
Tanner Pharma Group, a global provider of integrated specialty access solutions, has announced the signing of a distribution agreement with Nephcentric LLC, a developer and marketer of evidence based therapeutic options for people with kidney disease and metabolic disorders.
New findings from the international The Environmental Determinants of Diabetes in the Young (TEDDY) study add to a growing body of evidence indicating that type 1 diabetes is not a single disease. The presentation and, perhaps, cause of autoimmune diabetes differs among genetically high-risk children, the research suggests.
A multifunctional drug delivery system consisting of a lipid-based nanoparticle, a standard anticancer drug, and a short nucleic acid designed to augment the activity of that drug has demonstrated the ability to treat drug-resistant tumor cells.
› Verified 2 days ago